Jak2 mutation
DETECTION OF JAK2 MUTATION IN CASES OF MYELODYSPLASTIC SYNDROME
... gain-of-function mutation in exon 14 that results from a guanine- to-thymine transversion at nucleotide 1849 with substitution of valine to phenylalanine at codon ...of JAK2 mutation in cases of MDS ...
8
Original Article Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients
... of JAK2 mutation (V617F) in Egyptian patients with myeloproliferative disorders referred to National Cancer institute, Cairo ...for mutation detec- tion. Results: The frequency of the V617F ...
5
“Study of JAK2 V617F mutation, serum B12 level and interleukin – 23 level in polycythemia vera
... that mutation in tyrosine kinase JAK2V617F occurs in 95% of cases and a mutation in another exon of gene (exon 12) occurs in another 4% of cases of ...The JAK2 mutation also occurs in a ...
8
Fahrenkrog-Petersen, Leonie (2018): JAK2 V617F Mutationsanalysen an mikrodissektierten Zellen bei myeloproliferativen Neoplasien. Dissertation, LMU München: Medizinische Fakultät
... Die JAK2 V617F Mutation kann in heterozygoter (ein mutiertes Allel und ein Wildtyp-Allel), homozygoter (2 mutierte Allele) und hemizygoter (ein mutiertes Allel, das andere Allel fehlt) Form ...homozygote ...
108
<p>Analysis of the reannealing- instead of melting-curve in the detection of JAK2 V617F mutation by HRM method</p>
... cells. JAK2 mutation, called JAK2 V617F, is frequently found in Philadelphia chromosome-negative myeloproliferative ...for JAK2 V617F mutation ...for JAK2 V617F were examined by ...
7
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines
... heterozygous JAK2 mutation, in- dicating expression of both wild and mutant alleles in SET-2 cells (Figure ...to JAK2 is approximately 6:1 in SET 2 cells at both the genomic and cDNA ...of ...
6
JAK2 Mutations in Chronic Myeloproliferative Neoplasm; Towards the Application of Personalized Treatments for Saudi Patients
... kinase JAK2 mutations (exon 14 JAK2 V617F and exon 12) have significantly contributed to our understanding of the molecular mechanisms in the pathogenesis of Philadelphia negative CMPN such as polycythemia ...
5
The Prevalence of JAK2 -V617F Mutation in Sudanese Patients with Chronic Myeloproliferative Neoplasms
... the JAK2 mutation in 29 (57%) of 51 with ET, eight (50%) of 16 with idiopathic myelofibrosis, and 71 (97%) of 73 patients with ...the JAK2-V617F mutation in ...the JAK2-V617F ...the ...
7
Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis
... p.Arg652His mutation was suggested to explain the post-PV MF associated re- current ...a JAK2 mutation was ...the JAK2 exon 12 extra gel band was highly ...MEFV mutation, we performed ...
6
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
... V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)- negative subjects shows several mutations in exon ...Other mutation events as MPL, TET2, LNK, EZH2 have been described in ...
6
Impact of <em>JAK2</em>(<em>V617F</em>) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
... visits. JAK2 mutation status was measured in all patients at ...in JAK2-positive patients; allele burden was measured in both granulocyte DNA and platelet ...RNA. JAK2 mutation status ...
8
Evaluation of the JAK2 Gene Mutation in Moroccan Patients with Chronic Myeloproliferative Disorders
... point mutation is a G-C to T-A transversion, resulting in the substitution of valine by phenylalanine at codon 617 ...acquired mutation in the JAK2 gene on chromosome 9 in the majority of patients ...
8
Somatic CALR Mutations in myeloproliferative neoplasms with nonmutated JAK2
... nonmutated JAK2, in 8% of myelodysplasia samples, in occasional samples of other myeloid cancers, and in none of the other ...mutated JAK2. Mutation of CALR was detected in hematopoietic stem and ...
16
JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit)
... A 71-year old patient, male, former shepherd and farmer with seasonal periods spent at high altitude (3000 m), ex-smoker (60 pack/years), was referred by his general practitioner to our center for special- ist ...
5
JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia
... Ibrutinib has emerged in recent years as a very promising drug in B-CLL treatment, although few patients show mechanisms of resistance due to C481S mutation of BTK sequence preventing the irreversible binding of ...
13
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance
... of JAK2 was significantly increased after RT in all tested CRC cells, including patient-derived primary CRC cells and human CRC cell lines, while the in- crease in ATM transcription was statistically significant ...
18
Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
... of JAK2 exon 14 (V617F) mutation. Correct diagnosis of this mutation is very important as it is very rare in other similar disorders such as myelodysplasia, acute leukemia and other neoplasms without ...
7
Hepatic JAK2 protects against atherosclerosis through circulating IGF-1
... hepatic Jak2 disruption (22, 23), with accelerated atherosclerosis being attenuated with restoration of this axis, we cannot rule out other hepatic Jak2–mediated signalling pathways contributing to ...
18
Original Article Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer
... and JAK2 mRNA in 100 patients with gastric cancer and 50 healthy ...and/or JAK2 mRNA for gastric cancer. As- sociations of serum miR-375 and/or JAK2 mRNA levels with various clinicopathological ...
8
HSP90 is a therapeutic target in JAK2 dependent myeloproliferative neoplasms in mice and humans
... degrade JAK2 and inhibit JAK-STAT signaling markedly improves survival in the MPLW515L murine ...on JAK2/MPL mutant cells in vivo does not appear to result from increased dependence of mutant/activat- ed ...
17